Elevated Blood Levels of CCP Are Associated with Developing Rheumatoid Arthritis

In patients with joint pain, high baseline levels of cyclic citrullinated peptide mandate close follow-up.

Rheumatoid arthritis (RA) develops from an identifiable preclinical stage to frank disease. Previous European cohort studies have shown that patients who have arthralgia or undifferentiated arthritis and who are positive for cyclic citrullinated peptide (CCP) have excess risk for developing RA compared with CCP-negative patients. However, does the absolute level of CCP correlate with risk for RA development? In this retrospective study from a U.S. tertiary healthcare system, researchers clarified this association.

Researchers identified 340 patients who tested positive for CCP between 2009 and 2016 and met study criteria (i.e., were free of RA or other systemic rheumatic disease at the time of their first positive CCP result, had at least on…

Reviewing Author

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Elevated Blood Levels of CCP Are Associated with Developing Rheumatoid Arthritis

Topics

Reviewing Author